AbbVie Inc. (ABBV) FY2024 Annual P&L / Income Statement

AbbVie Inc. (ABBV) FY2024 Annual P&L / Income Statement

Income statement for 2024-01-01 through 2024-12-31. View: Key Product Portfolio by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenues

56,334,000,000 US dollars

Cost of products sold

16,904,000,000 US dollars

Gross profit (calculated)

39,430,000,000 US dollars

Operating expenses (calculated)

30,293,000,000 US dollars

Operating earnings

9,137,000,000 US dollars

Other income (expense), net (calculated)

negative 5,421,000,000 US dollars

Earnings before income tax expense

3,716,000,000 US dollars

Income tax expense (benefit)

negative 570,000,000 US dollars

Net earnings

4,286,000,000 US dollars

Aesthetics - Botox Cosmetic

2,720,000,000 US dollars

Aesthetics - Juvederm Collection

1,177,000,000 US dollars

Aesthetics - Other Aesthetics

1,279,000,000 US dollars

Eye Care - Alphagan/Combigan

248,000,000 US dollars

Eye Care - Lumigan/Ganfort

429,000,000 US dollars

Eye Care - Other Eye Care

847,000,000 US dollars

Eye Care - Ozurdex

494,000,000 US dollars

Eye Care - Restasis

224,000,000 US dollars

Oncology - Elahere

479,000,000 US dollars

Oncology - Epkinly

146,000,000 US dollars

Oncology - Imbruvica

3,347,000,000 US dollars

Oncology - Venclexta

2,583,000,000 US dollars

Immunology - Humira

8,993,000,000 US dollars

Immunology - Rinvoq

5,971,000,000 US dollars

Immunology - Skyrizi

11,718,000,000 US dollars

Neuroscience - Botox Therapeutic

3,283,000,000 US dollars

Neuroscience - Duodopa

447,000,000 US dollars

Neuroscience - Other Neuroscience

338,000,000 US dollars

Neuroscience - Qulipta

658,000,000 US dollars

Neuroscience - Ubrelvy

1,006,000,000 US dollars

Neuroscience - Vraylar

3,267,000,000 US dollars

Other Key Products - Linzess/Constella

954,000,000 US dollars

Other Key Products - Mavyret

1,311,000,000 US dollars

Undisclosed (calculated)

4,415,000,000 US dollars

Selling, general and administrative

14,752,000,000 US dollars

Research and development

12,791,000,000 US dollars

Acquired IPR&D and milestones

2,757,000,000 US dollars

Other operating expense (income), net

negative 7,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to AbbVie Inc.: $4.28 B; to noncontrolling interests: $8.00 M.